Delivery of sedative-hypnotics through an inhalation route
First Claim
1. A method of treating insomnia comprising administering a therapeutic amount of a sedative hypnotic drug condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% sedative hypnotic drug degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hypnotic drug is administered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% sedative-hypnotic drug degradation products. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route is provided which comprises: a) a thin coating of a sedative-hypnotic drug composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
21 Claims
-
1. A method of treating insomnia comprising administering a therapeutic amount of a sedative hypnotic drug condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% sedative hypnotic drug degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6)
-
7. A method of treating insomnia comprising administering a therapeutic amount of a zaleplon, zolpidem, or zopiclone condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% zaleplon, zolpidem, or zopiclone degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (8, 9, 10)
-
11. A method of administering a sedative hypnotic drug to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of a sedative hypnotic drug having less than 5% sedative hypnotic drug degradation products and an MMAD less than 3 microns wherein the peak plasma concentration of the sedative hypnotic drug is achieved in less than 0.1 hours.
-
12. A method of administering zaleplon, zolpidem, or zopiclone to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of zaleplon, zolpidem, or zopiclone having less than 5% zaleplon, zolpidem, or zopiclone degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of zaleplon, zolpidem, or zopiclone is achieved in less than 0.1 hours.
-
13. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an sedative hypnotic drug composition and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21)
-
Specification